TNFRSF17 and plasma cell myeloma: Various target antigens, including BCMA, CD19, CD38, CD44v6, CD138, GPRC5D, kappa light chain, FcRH5, CS1, integrin β7, and NKG2D, have been used to engineer CAR T cells to kill myeloma cells, with encouraging results.